Ann: IHL Provides Shareholder Information Events for Redomiciling, page-312

Bonus content.
Apnimed's incidence of insomnia was 15%.
Erectile dysfunction, 9%.

With these two side effects alone, assuming all those who suffer them decide to try IHL-42x instead, we already have a 24% advantage.
I cannot estimate how many more people will also shy away from Apnimed's drug because of the black box warnings of cardiovascular damage, suicide, and severe liver damage, but let's just say... quite a few more.

I hope this helps quantify our advantage to some degree.